Cysview: Who It’s For

Anyone who is suspected of having or is known to have bladder cancer (from a previous cystoscopy) can have BLC with Cysview.

Ideally, it should be used in:

  • first transurethral resection of bladder tumor (TURBT)
  • first follow-up cystoscopy
  • the management of intermediate-risk patients
  • the management of high-risk patients

For use in first TURBT and the management of intermediate and high-risk patients1

Recommended patient types2.3

  • Patients receiving first TURBT because of suspicion of non-muscle invasive bladder cancer (NMIBC)
  • Patients receiving repeat TURBT
  • Patients who received BCG treatment (to assess response)
  • Patients undergoing surveillance
  • Patients who will be receiving intravesical therapy when residual disease is suspected 
  • Patients with positive cytology and negative White Light Cystoscopy

1 Cysview [prescribing Information]. 2018:1-14.

2 Daneshmand S, Schuckman AK, Bochner BH, et al. Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle-Invasive Bladder Cancer: Review of the Clinical Evidence and Consensus Statement on Appropriate Use in the USA. Nat Rev Urol. 2014;11(10):589-596.

Lotan Y, Bivalacqua TJ, Downs T, et. al. Blue Light Flexible Cystoscopy with Hexaminolevulinate in Non-Muscle Invasive Bladder Cancer: Review of the Clinical Evidence and Consensus Statement on Optimal Use in the USA — Update 2018. Nat Rev Urol. 2019; pending. [Epub ahead of print].